Acromegaly

Orphanet Journal of Rare Diseases

Volumn 3, Issue 1, 2008, Pages

  Chanson, Philippe ^a,b,c   Salenave, Sylvie ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; FEMALE; HUMAN; HYPOPHYSIS TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RADIOGRAPHY; REVIEW; SECRETION;

ACROMEGALY; ADULT; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREVALENCE;

EID: 47349101228     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-3-17     Document Type: Review

References (103)

1. Epidemiology of acromegaly. IM Holdaway C Rajasoorya, Pituitary 1999 2 29 41 10.1023/A:1009965803750 11081170
2. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. AF Daly M Rixhon C Adam A Dempegioti MA Tichomirowa A Beckers, J Clin Endocrinol Metab 2006 91 4769 75 10.1210/jc.2006-1668 16968795
3. High prevalence of biochemical acromegaly in primary care patients with elevated insulin-like growth factor-1 levels. HJ Schneider C Sievers B Saller HU Wittchen GK Stalla, Clin Endocrinol (Oxf) 2008, Feb 13
4. Acromegaly. JD Nabarro, Clin Endocrinol (Oxf) 1987 26 481 512 10.1111/j.1365-2265.1987.tb00805.x 3308190
5. Acromegaly. Clinical and biochemical features in 500 patients. S Ezzat MJ Forster P Berchtold DA Redelmeier V Boerlin AG Harris, Medicine (Baltimore) 1994 73 233 40 7934807
6. Acromegaly. S Melmed, The Pituitaryed Malden, Mas, USA: Blackwell Science Inc, Melmed S, 2002 419 54
7. Les conséquences de l'acromégalie. P Chanson, Cachan: Éditions Médicales Internationales 2001
8. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. A Colao D Ferone P Marzullo G Lombardi, Endocr Rev 2004 25 102 52 10.1210/er.2002-0022 14769829
9. Diagnosis and treatment of acromegaly complications. A Giustina FF Casanueva F Cavagnini P Chanson D Clemmons LA Frohman R Gaillard K Ho P Jaquet DL Kleinberg SW Lamberts G Lombardi M Sheppard CJ Strasburger ML Vance JA Wass S Melmed, J Endocrinol Invest 2003 26 1242 7 15055479
10. Clinical manifestations of acromegaly. ME Molitch, Endocrinol Metab Clin North Am 1992 21 597 614 1521514
11. Rheumatologic and skeletal changes in acromegaly. SA Lieberman AG Bjorkengren AR Hoffman, Endocrinol Metab Clin North Am 1992 21 615 31 1521515
12. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. A Scillitani I Chiodini V Carnevale GM Giannatempo V Frusciante M Villella M Pileri G Guglielmi A Di Giorgio S Modoni S Fusilli A Di Cerbo A Liuzzi, J Bone Miner Res 1997 12 1729 36 10.1359/jbmr.1997.12.10.1729 9333135
13. Osteoarticular disorders of endocrine origin. F Liote P Orcel, Baillieres Best Pract Res Clin Rheumatol 2000 14 251 76 10.1053/berh.2000.0064 10925744
14. Hormone de croissance et manifestations rhumatologiques. F Lioté A Horusitzky P Chanson A Warnet, Les conséquences de l'acromé galieed Cachan: Éditions Médicales Internationales 2001 69 78
15. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. A Colao P Marzullo G Vallone V Marino M Annecchino D Ferone D De Brasi R Scarpa P Oriente G Lombardi, J Clin Endocrinol Metab 1998 83 2121 5 10.1210/jc.83.6.2121 9626149
16. The pathology of median neuropathy in acromegaly. PJ Jenkins SA Sohaib S Akker RR Phillips K Spillane JA Wass JP Monson AB Grossman GM Besser RH Reznek, Ann Intern Med 2000 133 197 201 10906834
17. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. P Chanson J Timsit C Masquet A Warnet PJ Guillausseau P Birman AG Harris J Lubetzki, Ann Intern Med 1990 113 921 5 2240917
18. Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in Acromegaly. P Kamenicky S Viengchareun A Blanchard G Meduri P Zizzari M Imbert-Teboul A Doucet P Chanson M Lombes, Endocrinology 2008, Apr 3 18388193
19. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. P Maison P Demolis J Young G Schaison JF Giudicelli P Chanson, Clin Endocrinol (Oxf) 2000 53 445 51 10.1046/j.1365-2265.2000.01127.x 11012569
20. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. A Colao R Baldelli P Marzullo E Ferretti D Ferone P Gargiulo M Petretta G Tamburrano G Lombardi A Liuzzi, J Clin Endocrinol Metab 2000 85 193 9 10.1210/jc.85.1.193 10634386
21. Relationship between blood pressure and glucose tolerance in acromegaly. ML Jaffrain-Rea C Moroni R Baldelli C Battista P Maffei M Terzolo M Correra MR Ghiggi E Ferretti A Angeli N Sicolo V Trischitta A Liuzzi R Cassone G Tamburrano, Clin Endocrinol (Oxf) 2001 54 189 95 10.1046/j.1365-2265.2001.01206. x 11207633
22. Growth hormone and the heart. L Sacca A Cittadini S Fazio, Endocr Rev 1994 15 555 73 10.1210/er.15.5.555 7843068
23. Cardiovascular function in acromegaly. RN Clayton, Endocr Rev 2003 24 272 7 10.1210/er.2003-0009 12788799
24. Long-term outcome of patients with acromegaly and congestive heart failure. H Bihan C Espinosa H Valdes-Socin S Salenave J Young S Levasseur P Assayag A Beckers P Chanson, J Clin Endocrinol Metab 2004 89 5308 13 10.1210/jc.2004-0821 15531475
25. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. A Colao L Spinelli P Marzullo R Pivonello M Petretta C Di Somma G Vitale D Bonaduce G Lombardi, J Clin Endocrinol Metab 2003 88 3196 201 10.1210/jc.2002-021099 12843165
26. Increased prevalence of regurgitant valvular heart disease in acromegaly. AM Pereira SW van Thiel JR Lindner F Roelfsema EE van der Wall H Morreau JW Smit JA Romijn JJ Bax, J Clin Endocrinol Metab 2004 89 71 5 10.1210/jc.2003- 030849 14715829
27. Alterations in body composition in acromegaly. L Katznelson, Pituitary 2008, Mar 28
28. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. BL Herrmann TE Wessendorf W Ajaj S Kahlke H Teschler K Mann, Eur J Endocrinol 2004 151 309 15 10.1530/eje.0.1510309 15362959
29. ® on sleep apneoa in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. MS Ip KC Tan WC Peh KS Lam, Clin Endocrinol 2001 55 4 477 83 10.1046/j.1365-2265.2001.01358.x
30. Acromegaly and cancer: not a problem? S Melmed, J Clin Endocrinol Metab 2001 86 2929 34 10.1210/jc.86.7.2929 11443145
31. Clinical perspective: acromegaly and cancer: a problem. PJ Jenkins M Besser, J Clin Endocrinol Metab 2001 86 2935 41 10.1210/jc.86.7.2935 11443146
32. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. AG Renehan J O'Connell D O'Halloran F Shanahan CS Potten ST O'Dwyer SM Shalet, Horm Metab Res 2003 35 712 25 10.1055/s-2004-814150 14710350
33. The prevalence of colonic polyps in acromegaly : a prospective colonoscopic and pathological study in 103 patients. B Delhougne C Deneux R Abs P Chanson H Fierens P Laurent-Puig I Duysburgh A Stevenaert A Tabarin J Delwaide, J Clin Endocrinol Metab 1995 80 3223 6 10.1210/jc.80.11.3223 7593429
34. Functional anatomy of the hypothalamic pituitary axis. SL Asa KT Kovacs S Melmed, The Pituitary Malden, Mas, USA: Blackwell Science Inc, Melmed S, 2 2002 3 44
35. Molecular targets in pituitary tumours. AP Heaney S Melmed, Nat Rev Cancer 2004 4 285 95 10.1038/nrc1320 15057288
36. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell. P Beck-Peccoz M Bassetti A Spada G Medri M Arosio G Giannattasio G Faglia, J Clin Endocrinol Metab 1985 61 541 6 2410443
37. Thyrotropin-secreting pituitary tumors. P Beck-Peccoz F Brucker-Davis L Persani RC Smallridge BD Weintraub, Endocr Rev 1996 17 610 38 10.1210/er.17.6.610 8969971
38. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. HV Socin P Chanson B Delemer A Tabarin V Rohmer J Mockel A Stevenaert A Beckers, Eur J Endocrinol 2003 148 433 42 10.1530/eje.0.1480433 12656664
39. Pituitary carcinoma: a clinicopathologic study of 15 cases. PJ Pernicone BW Scheithauer TJ Sebo KT Kovacs E Horvath WF Young Jr RV Lloyd DH Davis BL Guthrie WC Schoene, Cancer 1997 79 804 12 10.1002/(SICI)1097-0142(19970215)79: 4<804::AID-CNCR18>3.0.CO;2-3 9024719
40. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. K Kovacs R Lloyd E Horvath SL Asa L Stefaneanu DW Killinger HS Smyth, Am J Pathol 1989 134 345 53 2464941
41. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. EV Dimaraki CA Jaffe R DeMott-Friberg WF Chandler AL Barkan, J Clin Endocrinol Metab 2002 87 3537 42 10.1210/jc.87.8.3537 12161471
42. Medical progress: Acromegaly. S Melmed, N Engl J Med 2006 355 2558 73 10.1056/NEJMra062453 17167139
43. Clonal origin of pituitary adenomas. V Herman J Fagin R Gonsky K Kovacs S Melmed, J Clin Endocrinol Metab 1990 71 1427 30 1977759
44. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. L Vallar A Spada G Giannattasio, Nature 1987 330 566 8 10.1038/330566a0 2825031
45. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. G Vlotides T Eigler S Melmed, Endocr Rev 2007 28 165 86 10.1210/er.2006-0042 17325339
46. Mechanisms for pituitary tumorigenesis: the plastic pituitary. S Melmed, J Clin Invest 2003 112 1603 18 14660734
47. The pathogenesis of pituitary tumours. SL Asa S Ezzat, Nat Rev Cancer 2002 2 836 49 10.1038/nrc926 12415254
48. McCune-Albright syndrome in adulthood. P Chanson S Salenave P Orcel, Pediatr Endocrinol Rev 2007 4 Suppl 4 453 63 17982395
49. Guidelines for diagnosis and therapy of MEN type 1 and type 2. ML Brandi RF Gagel A Angeli JP Bilezikian P Beck-Peccoz C Bordi B Conte-Devolx A Falchetti RG Gheri A Libroia CJ Lips G Lombardi M Mannelli F Pacini BA Ponder F Raue B Skogseid G Tamburrano RV Thakker NW Thompson P Tomassetti F Tonelli SA Wells Jr SJ Marx, J Clin Endocrinol Metab 2001 86 5658 71 10.1210/jc.86.12.5658 11739416
50. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. B Vergès F Boureille P Goudet A Murat A Beckers G Sassolas P Cougard B Chambe C Montvernay A Calender, J Clin Endocrinol Metab 2002 87 457 65 10.1210/jc.87.2.457 11836268
51. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. LS Kirschner JA Carney SD Pack SE Taymans C Giatzakis YS Cho YS Cho-Chung CA Stratakis, Nat Genet 2000 26 89 92 10.1038/79238 10973256
52. Carney complex (CNC). J Bertherat, Orphanet J Rare Dis 2006 1 21 16756677 10.1186/1750-1172-1-21
53. Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene. O Vierimaa M Georgitsi R Lehtonen P Vahteristo A Kokko A Raitila K Tuppurainen TM Ebeling PI Salmela R Paschke S Gundogdu E De Menis MJ Makinen V Launonen A Karhu LA Aaltonen, Science 2006 312 1228 30 10.1126/science.1126100 16728643
54. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. L Cazabat R Libe K Perlemoine F Rene-Corail N Burnichon AP Gimenez-Roqueplo L Dupasquier-Fediaevsky X Bertagna E Clauser P Chanson J Bertherat ML Raffin-Sanson, Eur J Endocrinol 2007 157 1 8 10.1530/EJE-07-0181 17609395
55. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. A Barlier JF Vanbellinghen AF Daly M Silvy ML Jaffrain-Rea J Trouillas G Tamagno L Cazabat V Bours T Brue A Enjalbert A Beckers, J Clin Endocrinol Metab 2007 92 1952 5 10.1210/jc.2006-2702 17299063
56. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. AF Daly JF Vanbellinghen SK Khoo ML Jaffrain-Rea LA Naves MA Guitelman A Murat P Emy AP Gimenez-Roqueplo G Tamburrano G Raverot A Barlier W De Herder A Penfornis E Ciccarelli B Estour P Lecomte B Gatta O Chabre MI Sabate X Bertagna N Garcia Basavilbaso G Stalldecker A Colao P Ferolla JL Wemeau P Caron JL Sadoul A Oneto F Archambeaud A Calender O Sinilnikova CF Montanana F Cavagnini V Hana A Solano D Delettieres DC Luccio-Camelo A Basso V Rohmer T Brue V Bours BT Teh A Beckers, J Clin Endocrinol Metab 2007 92 1891 6 10.1210/jc.2006-2513 17244780
57. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. MO Thorner RL Perryman MJ Cronin AD Rogol M Draznin A Johanson W Vale E Horvath K Kovacs, J Clin Invest 1982 70 965 77 6290540 10.1172/JCI110708
58. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. S Melmed C Ezrin K Kovacs RS Goodman LA Frohman, N Engl J Med 1985 312 9 17 2981107
59. Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. F Beuschlein CJ Strasburger V Siegerstetter D Moradpour P Lichter M Bidlingmaier HE Blum M Reincke, N Engl J Med 2000 342 1871 6 10.1056/NEJM200006223422504 10861322
60. Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme. J Seth A Ellis R Al-Sadie, Horm Res 1999 51 Suppl 1 13 9 10.1159/000053130 10393486
61. Growth hormone heterogeneity in human pituitary and plasma. G Baumann, Horm Res 1999 51 Suppl 1 2 6 10.1159/000053128 10393484
62. Consensus statement on the standardisation of GH assays. PJ Trainer J Barth C Sturgeon G Wieringaon, Eur J Endocrinol 2006 155 1 2 10.1530/eje.1.02186 16793942
63. Criteria for cure of acromegaly: a consensus statement. A Giustina A Barkan FF Casanueva F Cavagnini L Frohman K Ho J Veldhuis J Wass K Von Werder S Melmed, J Clin Endocrinol Metab 2000 85 526 9 10.1210/jc.85.2.526 10690849
64. Editorial: acromegaly - consensus, what consensus? PJ Trainer, J Clin Endocrinol Metab 2002 87 3534 6 10.1210/jc.87.8.3534 12161470
65. Guidelines for acromegaly management. S Melmed FF Casanueva F Cavagnini P Chanson L Frohman A Grossman K Ho D Kleinberg S Lamberts E Laws G Lombardi ML Vance KV Werder J Wass A Giustina, J Clin Endocrinol Metab 2002 87 4054 8 10.1210/jc.2002-011841 12213843
66. Surgical management of acromegaly. R Fahlbusch J Honegger M Buchfelder, Endocrinol Metab Clin North Am 1992 21 669 92 1521518
67. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. B Swearingen FG Barker 2nd L Katznelson BM Biller S Grinspoon A Klibanski N Moayeri PM Black NT Zervas, J Clin Endocrinol Metab 1998 83 3419 26 10.1210/jc.83.10.3419 9768641
68. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. NR Biermasz H van Dulken F Roelfsema, J Clin Endocrinol Metab 2000 85 4596 602 10.1210/jc.85.12.4596 11134114
69. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. P Nomikos M Buchfelder R Fahlbusch, Eur J Endocrinol 2005 152 379 87 10.1530/eje.1.01863 15757854
70. Endoscopic endonasal transsphenoidal surgery. P Cappabianca LM Cavallo E de Divitiis, Neurosurgery 2004 55 933 40 discussion 40-1 10.1227/01.NEU. 0000137330.02549.0D 15458602
71. Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. P Cappabianca A Alfieri A Colao D Ferone G Lombardi E de Divitiis, Skull Base Surg 1999 9 109 17 17171126
72. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly [see comments]. AL Barkan I Halasz KJ Dornfeld CA Jaffe RD Friberg WF Chandler HM Sandler, J Clin Endocrinol Metab 1997 82 3187 91 10.1210/jc.82.10.3187 9329336
73. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. NR Biermasz H van Dulken F Roelfsema, J Clin Endocrinol Metab 2000 85 2476 82 10.1210/jc.85.7.2476 10902796
74. Comment et avec quelle efficacité traite-t-on l'acromégalie en 1997 ? Enquête transversale sur une population de 74 acromégales (Abst.). P Chanson P Grellier-Fouqueray J Young Y Le Bouc G Schaison, Ann Endocrinol (Paris) 1997 58 Suppl 2 2S69
75. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. G Barrande M Pittino-Lungo J Coste D Ponvert X Bertagna JP Luton J Bertherat, J Clin Endocrinol Metab 2000 85 3779 85 10.1210/jc.85.10.3779 11061538
76. The incidence of cerebrovascular accidents in patients with pituitary adenoma. M Brada L Burchell S Ashley D Traish, Int J Radiat Oncol Biol Phys 1999 45 693 8 10524424
77. Gamma knife radiosurgery in the management of patients with acromegaly: a review. AS Mahmoud-Ahmed JH Suh MR Mayberg, Pituitary 2001 4 223 30 10.1023/A:1020794329975 12501972
78. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. R Attanasio P Epaminonda E Motti E Giugni L Ventrella R Cozzi M Farabola P Loli P Beck-Peccoz M Arosio, J Clin Endocrinol Metab 2003 88 3105 12 10.1210/jc.2002-021663 12843150
79. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. F Castinetti D Taieb JM Kuhn P Chanson M Tamura P Jaquet B Conte-Devolx J Regis H Dufour T Brue, J Clin Endocrinol Metab 2005 90 4483 8 10.1210/jc.2005-0311 15899958
80. Medical therapy for acromegaly. CB Newman, Endocrinol Metab Clin North Am 1999 28 171 90 10.1016/S0889-8529(05)70062-1 10207690
81. Cabergoline in the treatment of acromegaly: a study in 64 patients. R Abs J Verhelst D Maiter K Van Acker F Nobels JL Coolens C Mahler A Beckers, J Clin Endocrinol Metab 1998 83 374 8 10.1210/jc.83.2.374 9467544
82. Octreotide. SW Lamberts AJ van der Lely WW de Herder LJ Hofland, N Engl J Med 1996 334 246 54 10.1056/NEJM199601253340408 8532003
83. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 - approximately equal to Acromegaly Study Group. G Sassolas AG Harris A James-Deidier, J Clin Endocrinol Metab 1990 71 391 7 2199479
84. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. P Chanson J Timsit AG Harris, Clin Pharmacokinet 1993 25 375 91 8287633
85. Octreotide as primary therapy for acromegaly. CB Newman S Melmed A George D Torigian M Duhaney P Snyder W Young A Klibanski ME Molitch R Gagel L Sheeler D Cook W Malarkey I Jackson ML Vance A Barkan L Frohman DL Kleinberg, J Clin Endocrinol Metab 1998 83 3034 40 10.1210/jc.83.9.3034 9745397
86. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. JC Gillis S Noble KL Goa, Drugs 1997 53 681 99 10.2165/00003495-199753010-00012 9098666
87. Somatostatin analogs in acromegaly. PU Freda, J Clin Endocrinol Metab 2002 87 3013 8 10.1210/jc.87.7.3013 12107192
88. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. A Colao D Ferone P Marzullo P Cappabianca S Cirillo V Boerlin I Lancranjan G Lombardi, J Clin Endocrinol Metab 2001 86 2779 86 10.1210/jc.86.6.2779 11397887
89. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. P Chanson V Boerlin C Ajzenberg Y Bachelot P Benito J Bringer P Caron B Charbonnel C Cortet B Delemer F Escobar-Jimenez L Foubert S Gaztambide F Jockenhoevel JM Kuhn J Leclere Y Lorcy L Perlemuter H Prestele P Roger V Rohmer R Santen G Sassolas WA Scherbaum J Schopohl E Torres, Clin Endocrinol (Oxf) 2000 53 577 86 10.1046/j.1365-2265.2000.01134.x 11106918
90. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. P Caron A Beckers DR Cullen MI Goth B Gutt P Laurberg AM Pico M Valimaki W Zgliczynski, J Clin Endocrinol Metab 2002 87 99 104 10.1210/jc.87.1.99 11788630
91. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow- release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. JS Bevan SL Atkin AB Atkinson PM Bouloux F Hanna PE Harris RA James M McConnell GA Roberts MF Scanlon PM Stewart E Teasdale HE Turner JA Wass JM Wardlaw, J Clin Endocrinol Metab 2002 87 4554 63 10.1210/jc.2001-012012 12364434
92. Effect of octreotide pretreatment on surgical outcome in acromegaly. A Colao D Ferone P Cappabianca ML del Basso De Caro P Marzullo A Monticelli A Alfieri B Merola A Cali E de Divitiis G Lombardi, J Clin Endocrinol Metab 1997 82 3308 14 10.1210/jc.82.10.3308 9329359
93. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. P Petrossians L Borges-Martins C Espinoza A Daly D Betea H Valdes-Socin A Stevenaert P Chanson A Beckers, Eur J Endocrinol 2005 152 61 6 10.1530/eje.1.01824 15762188
94. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. JJ Kopchick C Parkinson EC Stevens PJ Trainer, Endocr Rev 2002 23 623 46 10.1210/er.2001-0022 12372843
95. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. PJ Trainer WM Drake L Katznelson PU Freda V Herman-Bonert AJ van der Lely EV Dimaraki PM Stewart KE Friend ML Vance GM Besser JA Scarlett MO Thorner C Parkinson A Klibanski JS Powell AL Barkan MC Sheppard M Malsonado DR Rose DR Clemmons G Johannsson BA Bengtsson S Stavrou DL Kleinberg DM Cook LS Phillips M Bidlingmaier CJ Strasburger S Hackett K Zib WF Bennett RJ Davis, N Engl J Med 2000 342 1171 7 10.1056/NEJM200004203421604 10770982
96. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. AJ van der Lely RK Hutson PJ Trainer GM Besser AL Barkan L Katznelson A Klibanski V Herman-Bonert S Melmed ML Vance PU Freda PM Stewart KE Friend DR Clemmons G Johannsson S Stavrou DM Cook LS Phillips CJ Strasburger S Hackett KA Zib RJ Davis JA Scarlett MO Thorner, Lancet 2001 358 1754 9 10.1016/S0140-6736(01)06844-1 11734231
97. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. AJ van der Lely A Muller JA Janssen RJ Davis KA Zib JA Scarlett SW Lamberts, J Clin Endocrinol Metab 2001 86 478 81 10.1210/jc.86.2.478 11157994
98. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. I Schreiber M Buchfelder M Droste K Forssmann K Mann B Saller CJ Strasburger, Eur J Endocrinol 2007 156 75 82 10.1530/eje.1.02312 17218728
99. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Ayuk RN Clayton G Holder MC Sheppard PM Stewart AS Bates, J Clin Endocrinol Metab 2004 89 1613 7 10.1210/jc.2003-031584 15070920
100. A nationwide survey of mortality in acromegaly. R Kauppinen-Mäkelin T Sane A Reunanen MJ Välimäki L Niskanen H Markkanen E Löyttyniemi T Ebeling P Jaatinen H Laine P Nuutila P Salmela J Salmi UH Stenman J Viikari E Voutilainen, J Clin Endocrinol Metab 2005 90 4081 6 10.1210/jc.2004-1381 15886256
101. Factors influencing mortality in acromegaly. IM Holdaway RC Rajasoorya GD Gamble, J Clin Endocrinol Metab 2004 89 667 74 10.1210/jc.2003-031199 14764779
102. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. NR Biermasz SW van Thiel AM Pereira HC Hoftijzer AM van Hemert JW Smit JA Romijn F Roelfsema, J Clin Endocrinol Metab 2004 89 5369 76 10.1210/jc.2004-0669 15531483
103. Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. P Maison P Chanson, Nat Clin Pract Endocrinol Metab 2006 2 650 1 10.1038/ncpendmet0350 17143307